Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04080505 · ClinicalTrials.gov registry record · Phase 3

Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?

A Phase 3 study, sponsored by Columbia University.

Terminated
Registry status
Phase 3
Development phase
29
Enrollment target

NCT04080505: Clinical Trial Phase 3 study, sponsored by Columbia University.

NCT04080505 is a Phase 3 study that was terminated before completion, run by Columbia University. The registered enrollment target is 29 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04080505, a Phase 3 study, was terminated before completion, sponsored by Columbia University.

TERMINATED
Registry status
Phase 3
Development phase
29 participants
Enrollment target

Study Summary

The purpose of this research is to find out if SSKI (Potassium Iodide) reduces vascularity (the number and concentration of blood vessels) and improves how well patients do after surgery for removal of their whole thyroid gland in Graves' disease (an autoimmune disease that is a common cause of hyperthyroidism).

Primary Outcome

Using 3D imaging software, the investigators will quantify the vascular flow in the ultrasound images and compare baseline images with the operating room (OR) images to assess if there is a difference in vascular flow between those timepoints. Vascular flow will be quantified using percent (%) surface area. This calculation will be done by a computer algorithm.

Interventions

  • DRUG SSKI- Potassium Iodide

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2015-02-10
Est. Completion 2023-03-03
Phase Phase 3
Columbia University

958 total trials

Why NCT04080505 stopped before completion

NCT04080505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which SSKI- Potassium Iodide is the first listed.

NCT04080505 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04080505 about?

NCT04080505 is a clinical study titled "Does Potassium Iodide (SSKI) Reduce Vascularity in Graves' Thyroidectomy?". The purpose of this research is to find out if SSKI (Potassium Iodide) reduces vascularity (the number and concentration of blood vessels) and improves how well patients do after surgery for removal of their whole thyroid gland in Graves' disease (an autoimmune disease that is a common cause of hype...

What is the current status of trial NCT04080505?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2015-02-10. Estimated completion is 2023-03-03.

What interventions are being tested in trial NCT04080505?

The interventions under investigation include: SSKI- Potassium Iodide (DRUG).

Who is sponsoring clinical trial NCT04080505?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04080505's enrollment target sits among peer trials

29 1933rd of 2000 higher than 66 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02429557 · 29 participants · Phase 1

    Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure

  • NCT02568878 · 29 participants · Phase 3

    Creatine for Depressed Male and Female Methamphetamine Users

  • NCT03014401 · 29 participants · NA

    The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis

  • NCT03128996 · 29 participants · Phase 1

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04080505, the US trial registry maintained by the National Library of Medicine. NCT04080505 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.